Merk Verena M, Boonen Georg, Butterweck Veronika, Schapowal Andreas
Medical Department, Max Zeller Söhne AG, 8590 Romanshorn, Switzerland.
Schweizerische Medizinische Gesellschaft für Phytotherapie, 8021 Zurich, Switzerland.
Adv Respir Med. 2025 Jun 3;93(3):13. doi: 10.3390/arm93030013.
Allergic rhinitis (AR) is a global health problem on the rise. More and more people are affected, and climate change is exacerbating this health problem in the long term. The quality of life of those affected is often severely compromised, and the financial burden on healthcare systems cannot be disregarded. Therefore, effective and safe medicines are needed to counteract this trend. (butterbur) leaf extract (Ze 339) displays a promising alternative to antihistamines in the treatment of AR symptoms. More than two decades after the first market launch it is now possible to draw a meaningful conclusion on its safety and efficacy. This review summarizes the available preclinical and clinical data, real-world data (RWD) as well as data from post-marketing pharmacovigilance monitoring about the herbal medicinal drug Ze 339. It focusses on the current knowledge about the mode of action as well as the evaluation of its efficacy and safety in the treatment of AR. Given its favourable safety profile and lack of sedative side effects, Ze 339 offers a valuable alternative to antihistamines and should therefore continue to be considered by medical practitioners for the treatment of allergic rhinitis symptoms.
变应性鼻炎（AR）是一个日益严重的全球性健康问题。受影响的人越来越多，从长远来看，气候变化正在加剧这一健康问题。患者的生活质量常常受到严重影响，医疗系统的经济负担也不容忽视。因此，需要有效且安全的药物来扭转这一趋势。（款冬）叶提取物（Ze 339）在治疗AR症状方面显示出一种有望替代抗组胺药的选择。在首次上市二十多年后，现在可以就其安全性和有效性得出有意义的结论。本综述总结了关于草药Ze 339的现有临床前和临床数据、真实世界数据（RWD）以及上市后药物警戒监测数据。它聚焦于当前关于其作用模式的知识以及对其治疗AR的有效性和安全性的评估。鉴于其良好的安全性和无镇静副作用，Ze 339为抗组胺药提供了一种有价值的替代选择，因此医疗从业者在治疗变应性鼻炎症状时应继续考虑使用它。
Zotero 插件
